Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astra Tech buys Atlantis

This article was originally published in The Gray Sheet

Executive Summary

Dental implant maker Atlantis Components is being acquired for $71 million by Swedish dental implant firm Astra Tech, a unit of AstraZeneca, announced Sept. 27. The purchase of Cambridge, Mass.-based Atlantis includes advanced digital CAD/CAM computer-aided design/computer-aided manufacturing technology that will help Astra Tech tailor implant abutments to individual patient requirements. The deal also boosts Astra Tech's North American presence, and adds Atlantis' $25 million in sales forecasted for 2008. Meanwhile, Atlantis' dental implant offerings will gain expanded market penetration. Astra Tech, which generated 2006 revenue of $414 million, says it has been able to grow at a 40%-plus rate over the past few years while the global dental implant market has expanded at a 20% rate

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel